Follow-The-Filings

Security · featured owners

KRYS Krystal Biotech Inc.

Health Care COM Equity as of 2026 Q2 among managers we track

  • 1 Owner
  • Max 0.6%
  • $5M
  • 1 add 1 exit

KRYS (Krystal Biotech Inc.) is held in 1 featured 13F book as of 2026 Q2. Torray Investment Partners is the largest tracked holder by portfolio weight (0.61%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 0.6% (Torray Investment Partners) · not free-float ownership

  1. Torray Investment Partners add 0.61%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Torray Investment Partners 2026 Q2 0.61% Add +1.0% 12,156 $5M history
Farallon Capital Management exited 2026 Q2 last 2026 Q1 <0.01% Exit 0.00% 1,000 $258K history

1 current · 1 exited last period · options excluded

SEC filings

Recent issuer filings from EDGAR · 19 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 5.07 Filing Doc
10-Q Filing Doc
8-K 9.01 Filing Doc
DEFA14A Filing Doc
10-K Filing Doc
8-K 2.02 Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
8-K 7.01,9.01 Filing Doc
8-K 5.02,9.01 Filing Doc
10-Q Filing Doc
8-K 2.02 Filing Doc
8-K 8.01 Filing Doc
10-Q Filing Doc
8-K 2.02,9.01 Filing Doc
8-K 7.01 Filing Doc
8-K 7.01 Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 13 rows shown

Filed Form Detail Links
4 Period Sep 4, 2026 · 2 forms Filing Doc
4 Period Aug 14, 2026 Filing Doc
4 Period Jun 25, 2026 Filing Doc
4 Period Jun 4, 2026 · 2 forms Filing Doc
4 Period May 26, 2026 Filing Doc
4 Period Mar 4, 2026 · 2 forms Filing Doc
4 Period Feb 27, 2026 · 4 forms Filing Doc
4 Period Feb 24, 2026 Filing Doc
4 Period Feb 19, 2026 Filing Doc
4 Period Feb 9, 2026 Filing Doc
4 Period Dec 4, 2025 · 2 forms Filing Doc
4 Period Jul 14, 2025 · 2 forms Filing Doc
4 Period Jul 9, 2025 Filing Doc

Updated 7 days ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $50.7M $290.52M $389.13M
Net income $10.93M $89.16M $204.83M
Net margin * 21.6% 30.7% 52.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $0.588B $0.742B $1.02B
Total non-current assets * $230.45M $313.79M $309.19M
Total assets $0.818B $1.06B $1.33B
Total current liabilities $33.09M $102M $102.94M
Total non-current liabilities * $6.62M $7.46M $11.29M
Total equity $0.779B $0.946B $1.22B

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$88.8M $123.42M $200.86M
Cash from investing $82.64M -$163.44M -$58.42M
Cash from financing $202.75M $27.01M $8.7M
Net change in cash $196.43M -$13.46M $151.44M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders